Related Experiment Videos
Marrow transplantation for stable-phase chronic granulocytic leukemia
Experimental Hematology
|October 1, 1984
Summary
Bone marrow transplantation can eliminate Philadelphia chromosome-positive cells in chronic granulocytic leukemia patients. This procedure offers a relatively safe and effective treatment option for stable-phase disease.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Chronic granulocytic leukemia (CGL) is characterized by the Philadelphia chromosome.
- Stable-phase CGL patients represent a unique group for therapeutic interventions.
Purpose of the Study:
- To evaluate the efficacy and safety of bone marrow transplantation (BMT) in stable-phase CGL.
- To assess the elimination of the abnormal myeloid clone post-BMT.
Main Methods:
- Ten patients with stable-phase CGL received BMT from HLA-identical siblings or an identical twin.
- Conditioning regimen included cytarabine, cyclophosphamide, and total body irradiation.
- Marrow cytogenetics were analyzed pre- and post-transplantation.
Main Results:
- All patients achieved cytogenetically normal marrow post-transplantation.
- Leukemia recurrence was observed only in the syngeneic transplant recipient.
- Nine out of ten patients survived long-term (median 597 days).
Conclusions:
- BMT effectively eradicates the abnormal myeloid clone in stable-phase CGL.
- BMT is a relatively safe and curative option for this patient population.